Nicox SA (Euronext Growth Paris: FR0013018124, ALCOX), an international ophthalmology company, today announced that the last patient completed their final visit in the Whistler Phase 3b clinical trial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback